top of page

BackTable / VI / Podcast / Episode #256

Origins of TACE

with Dr. Michael Soulen and Dr. Nicholas Fidelman

In this episode, guest host Dr. Nicholas Fidelman interviews Dr. Michael Solen, a key player in the development and widespread adoption of transarterial chemoembolization (TACE). The doctors discuss how TACE became a major therapeutic option for liver tumors, his preferred method of TACE dosage and management, and exciting new frontiers in chemoembolization.

Sponsored by:

Varian
Origins of TACE with Dr. Michael Soulen and Dr. Nicholas Fidelman on the BackTable VI Podcast)
Ep 256 Origins of TACE with Dr. Michael Soulen and Dr. Nicholas Fidelman
00:00 / 01:04

BackTable, LLC (Producer). (2022, October 28). Ep. 256 – Origins of TACE [Audio podcast]. Retrieved from https://www.backtable.com

BackTable CMEfy button

Stay Up To Date

Follow:

Subscribe:

Sign Up:

Podcast Contributors

Dr. Michael Soulen discusses Origins of TACE on the BackTable 256 Podcast

Dr. Michael Soulen

Dr. Michael Soulen is an interventional radiologist and a professor of radiology at the University of Pennsylvania.

Dr. Nicholas Fidelman discusses Origins of TACE on the BackTable 256 Podcast

Dr. Nicholas Fidelman

Dr. Nicholas Fidelman is an interventional radiologist and the director of Interventional Oncology at UCSF in San Francisco.

Show Notes

Dr. Soulen recalls his first ever TACE patient, who was a patient self-referring for a rare neuroendocrine tumor. As an IR fellow at the University of Pennsylvania, Dr. Soulen recognized the opportunity to incorporate clinic time into his IR practice. His push for clinical management of IR patients resulted in successful medical and financial outcomes, which also led his hospital to establishing an interventional oncology clinic. He emphasizes that a clinic presence is crucial to participating in tumor boards and being able to accept outside referrals.

Next, we delve into the history of the CAM (cisplatin, adriamycin, mitomycin) conventional TACE cocktail, which Dr. Soulen developed alongside medical oncologists and pharmacists. These chemotherapeutics, combined with lipiodol and followed by particle embolics, make up the most widely used TACE protocol in the United States. Dr. Soulen reviews his preferred ratios and mixing method for maximal efficacy. He discusses his current RETNET trial that directly compares treatment of neuroendocrine tumors with conventional TACE versus bland embolization in terms of progression free survival, toxic side effects, and patient quality of life.

Additionally, we address the high prevalence of post-embolization syndrome and SIR consensus guidelines for its management. Since chemoembolization is a highly emetogenic therapy, Dr. Soulen uses an oncology evidence-based combination of Benadryl, Zofran, and Decadron. He administers PRN pain medication on an individual patient basis. Furthermore, we discuss post-TACE management, specifically length of hospital stay. While all patients used to be admitted for overnight monitoring, this has shifted to mostly same-day discharges. This change has allowed the hospital to conserve resources and decrease costs.

Finally, Dr. Soulen shares his perspective on new developments in interventional oncology. He highlights a need to identify TACE drugs that specifically target intratumoral hypoxic response mechanisms. He also compares transarterial radioembolization (TARE) to TACE, noting that the former has not shown superiority to systemic therapy in research trials. However, there are possibilities that TARE or TACE could be useful to slow tumor progression in radiation lobectomy or as immunostimulants for combination therapy with immune checkpoint inhibitors and CAR-T cell therapy.

Resources

RETNET Trial:
https://clinicaltrials.gov/ct2/show/NCT02724540

Transcatheter oily chemoembolization of hepatocellular carcinoma:
https://pubmed.ncbi.nlm.nih.gov/2536946/

Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816794/

Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma:
https://pubmed.ncbi.nlm.nih.gov/24937669/

Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion:
https://pubmed.ncbi.nlm.nih.gov/26390875/

Outpatient Transarterial Chemoembolization of Hepatocellular Carcinoma: Review of a Same-Day Discharge Strategy:
https://pubmed.ncbi.nlm.nih.gov/29478795/

Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139681/

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

Earn CME When You Listen to BackTable CMEfy

Up Next

Ortho / IR Collaboration in Private Practice with Dr. Daniel Lerman and Dr. Anthony Brown on the BackTable VI Podcast)
The TheraSphere Story with Dr. Riad Salem and Peter Pattison on the BackTable VI Podcast)
Microwave Ablation for Liver Lesions with Dr. Josh Kuban on the BackTable VI Podcast)
History of Ablative Procedures with Dr. Luigi Solbiati and Dr. Steven Raman on the BackTable VI Podcast)
Who is SIO? Past, Present and Future of Our Society with Dr. Bill Rilling, Dr. Sarah White, and Dr. Sean Tutton on the BackTable VI Podcast)
Minimizing Complications for Lung Biopsies with Dr. Robert Suh on the BackTable VI Podcast)

Articles

Topics

Hepatocellular Carcinoma Condition Overview
Learn about Interventional Oncology on BackTable VI
TACE Procedure Steps & Treatment

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.

Select which show(s) you would like to subscribe to:

Thanks! Message sent.

bottom of page